| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
272,790,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Taysha Gene Therapies is a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations. Co. owns the exclusive worldwide rights to a clinical-stage, intrathecally dosed AAV9 gene therapy program, known as TSHA-120, for the treatment of giant axonal neuropathy (GAN). GAN is a rare autosomal recessive disease of the central and peripheral nervous systems caused by loss-of-function gigaxonin gene mutations. TSHA-120 is an AAV9 self-complementary viral vector encoding the full length human gigaxonin protein.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
750,000 |
2,083,333 |
| Total Buy Value |
$0 |
$0 |
$2,062,500 |
$5,062,499 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
2 |
| Total Shares Sold |
370,172 |
681,717 |
681,717 |
681,717 |
| Total Sell Value |
$1,695,906 |
$2,659,809 |
$2,659,809 |
$2,659,809 |
| Total People Sold |
1 |
2 |
2 |
2 |
| Total Sell Transactions |
2 |
5 |
5 |
5 |
| End Date |
2025-09-11 |
2025-06-10 |
2024-12-10 |
2023-12-11 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-12-01 |
4 |
S |
$4.51 |
$1,172,812 |
D/D |
(260,047) |
1,006,439 |
|
- |
|
| Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-12-01 |
4 |
OE |
$1.71 |
$444,680 |
D/D |
260,047 |
1,266,486 |
|
- |
|
| Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-11-28 |
4 |
S |
$4.75 |
$523,094 |
D/D |
(110,125) |
1,006,439 |
|
- |
|
| Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-11-28 |
4 |
OE |
$0.70 |
$117,363 |
D/D |
110,125 |
1,116,564 |
|
- |
|
| Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-09-10 |
4 |
AS |
$3.23 |
$646,000 |
D/D |
(200,000) |
1,006,439 |
|
- |
|
| Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-09-10 |
4 |
OE |
$0.70 |
$28,760 |
D/D |
41,150 |
1,206,439 |
|
- |
|
| Alam Kamran |
CHIEF FINANCIAL OFFICER |
• – – |
2025-08-21 |
4 |
S |
$2.85 |
$155,299 |
D/D |
(54,491) |
1,187,603 |
|
- |
|
| Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-08-21 |
4 |
S |
$2.85 |
$162,604 |
D/D |
(57,054) |
1,165,289 |
|
- |
|
| Stalfort Sean |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
56,623 |
1,155,224 |
|
- |
|
| Donenberg Philip B |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
56,623 |
219,954 |
|
- |
|
| Long Alison S |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
56,623 |
105,843 |
|
- |
|
| Sepp-Lorenzino Laura |
|
– • – |
2025-06-02 |
4 |
A |
$0.00 |
$0 |
D/D |
56,623 |
105,843 |
|
- |
|
| Manning Paul B |
|
– – • |
2025-05-30 |
4 |
B |
$2.75 |
$2,062,500 |
I/I |
750,000 |
2,841,704 |
0.01 |
- |
|
| Alam Kamran |
CHIEF FINANCIAL OFFICER |
• – – |
2025-03-11 |
4 |
D |
$1.69 |
$50,435 |
D/D |
(29,843) |
1,242,094 |
|
- |
|
| Nagendran Sukumar |
President and Head of R&D |
• • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
324,500 |
1,222,343 |
|
- |
|
| Alam Kamran |
CHIEF FINANCIAL OFFICER |
• – – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
431,000 |
1,271,937 |
|
- |
|
| Nolan Sean P. |
Chief Executive Officer |
• • – |
2025-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
892,500 |
2,078,358 |
|
- |
|
| Manning Paul B |
|
– – • |
2024-06-27 |
4 |
B |
$2.25 |
$2,999,999 |
D/D |
1,333,333 |
1,333,333 |
0.01 |
- |
|
| Donenberg Philip B |
|
– • – |
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
49,220 |
163,331 |
|
- |
|
| Long Alison S |
|
– • – |
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
49,220 |
49,220 |
|
- |
|
| Stalfort Sean |
|
– • – |
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
49,220 |
1,098,601 |
|
- |
|
| Sepp-Lorenzino Laura |
|
– • – |
2024-05-29 |
4 |
A |
$0.00 |
$0 |
D/D |
49,220 |
49,220 |
|
- |
|
| Alam Kamran |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-02 |
4 |
D |
$1.51 |
$1,945 |
D/D |
(1,288) |
840,937 |
|
- |
|
| Alam Kamran |
Chief Financial Officer |
• – – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
590,413 |
842,225 |
|
- |
|
| Nolan Sean P. |
Chief Executive Officer |
• • – |
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,184,688 |
1,185,858 |
|
- |
|
81 Records found
|
|
Page 1 of 4 |
|
|
